Nanobac Historical Financial Ratios

NNBP Stock  USD 0.0001  0.00  0.00%   
Nanobac Pharmaceuticals is lately reporting on over 61 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Average Payables of 394.7 K will help investors to properly organize and evaluate Nanobac Pharmaceuticals financial condition quickly.
  
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nanobac Pharmaceuticals Incorporated. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

About Nanobac Financial Ratios Analysis

Nanobac PharmaceuticalsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Nanobac Pharmaceuticals investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Nanobac financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Nanobac Pharmaceuticals history.

Nanobac Pharmaceuticals Financial Ratios Chart

At this time, Nanobac Pharmaceuticals' ROE is relatively stable compared to the past year.
Add Fundamental
Price To Sales RatioPtb Ratio
Days Sales OutstandingBook Value Per Share
Free Cash Flow YieldInvested Capital
Operating Cash Flow Per ShareAverage Payables
Stock Based Compensation To RevenueCapex To Depreciation
Pb RatioEv To Sales
Free Cash Flow Per ShareRoic
Inventory TurnoverNet Income Per Share
Days Of Inventory On HandPayables Turnover
Sales General And Administrative To RevenueAverage Inventory
Research And Ddevelopement To RevenueCapex To Revenue
Cash Per SharePocfratio
Interest CoveragePayout Ratio
Capex To Operating Cash FlowPfcf Ratio
Days Payables OutstandingNet Current Asset Value
Income QualityRoe
Tangible Asset ValueEv To Operating Cash Flow
Pe RatioReturn On Tangible Assets
Ev To Free Cash FlowIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Graham NumberShareholders Equity Per Share
Debt To EquityCapex Per Share
Graham Net NetAverage Receivables
Revenue Per ShareInterest Debt Per Share
Debt To AssetsEnterprise Value Over E B I T D A
Dividend YieldEarnings Yield
Short Term Coverage RatiosPrice Earnings Ratio
Operating CyclePrice Book Value Ratio
Price Earnings To Growth RatioDays Of Payables Outstanding
Dividend Payout RatioPrice To Operating Cash Flows Ratio
Price To Free Cash Flows RatioPretax Profit Margin
Ebt Per EbitOperating Profit Margin
Effective Tax RateCompany Equity Multiplier
Long Term Debt To CapitalizationTotal Debt To Capitalization
Return On Capital EmployedDebt Equity Ratio
Ebit Per RevenueQuick Ratio
Dividend Paid And Capex Coverage RatioNet Income Per E B T
Cash RatioCash Conversion Cycle
Operating Cash Flow Sales RatioDays Of Inventory Outstanding
Days Of Sales OutstandingFree Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage RatiosPrice To Book Ratio
Fixed Asset TurnoverCapital Expenditure Coverage Ratio
Price Cash Flow RatioEnterprise Value Multiple
Debt RatioCash Flow To Debt Ratio
Price Sales RatioReturn On Assets
Asset TurnoverNet Profit Margin
Gross Profit MarginPrice Fair Value
Return On Equity

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Nanobac Pharmaceuticals stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Nanobac Pharmaceuticals sales, a figure that is much harder to manipulate than other Nanobac Pharmaceuticals Incorporated multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Free Cash Flow Yield

A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.

Operating Cash Flow Per Share

A measure of the cash generated from a company's normal business operations per share, indicating how much cash is generated from a company's business operations on a per-share basis.

Average Payables

The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.

Capex To Depreciation

The ratio of a company's capital expenditures to its depreciation expenses, indicating how much the company is investing in physical assets relative to the aging of existing assets.

Ev To Operating Cash Flow

A valuation metric comparing the company's enterprise value to its operating cash flow, indicating how many dollars of EV are generated for each dollar of operating cash flows.
Most ratios from Nanobac Pharmaceuticals' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Nanobac Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nanobac Pharmaceuticals Incorporated. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.
At this time, Nanobac Pharmaceuticals' ROE is relatively stable compared to the past year.
 2010 2011 2023 2024 (projected)
Payables Turnover3.20.01350.01550.0147
Days Of Inventory On Hand239.29259.01233.11168.33

Nanobac Pharmaceuticals fundamentals Correlations

-0.96-0.82-0.99-0.86-0.98-0.99-0.99-0.960.990.981.0-0.50.990.28-0.99-0.99-0.78-0.99-0.99-0.990.941.0-0.981.0-0.95
-0.960.630.990.970.990.990.991.0-0.98-0.99-0.980.25-0.99-0.010.990.990.790.990.990.99-0.99-0.970.95-0.971.0
-0.820.630.720.450.720.740.720.63-0.72-0.72-0.760.73-0.72-0.780.720.720.450.720.740.72-0.61-0.770.83-0.770.61
-0.990.990.720.931.01.01.00.99-0.99-1.0-0.990.36-1.0-0.121.01.00.81.01.01.0-0.98-0.990.97-0.990.99
-0.860.970.450.930.930.920.930.97-0.91-0.93-0.890.0-0.930.20.930.930.690.930.910.93-0.98-0.890.87-0.890.98
-0.980.990.721.00.931.01.00.99-0.99-1.0-0.990.36-1.0-0.121.01.00.791.01.01.0-0.98-0.990.97-0.990.99
-0.990.990.741.00.921.01.00.99-1.0-1.0-1.00.4-1.0-0.151.01.00.811.01.01.0-0.97-1.00.97-1.00.98
-0.990.990.721.00.931.01.00.99-0.99-1.0-0.990.36-1.0-0.121.01.00.81.01.01.0-0.98-0.990.97-0.990.99
-0.961.00.630.990.970.990.990.99-0.98-0.99-0.980.25-0.99-0.010.990.990.790.990.990.99-0.99-0.970.95-0.971.0
0.99-0.98-0.72-0.99-0.91-0.99-1.0-0.99-0.980.991.0-0.420.990.12-0.99-0.99-0.85-0.99-1.0-0.990.961.0-0.951.0-0.98
0.98-0.99-0.72-1.0-0.93-1.0-1.0-1.0-0.990.990.99-0.361.00.12-1.0-1.0-0.79-1.0-1.0-1.00.980.99-0.970.99-0.99
1.0-0.98-0.76-0.99-0.89-0.99-1.0-0.99-0.981.00.99-0.450.990.19-0.99-1.0-0.82-0.99-1.0-0.990.961.0-0.971.0-0.97
-0.50.250.730.360.00.360.40.360.25-0.42-0.36-0.45-0.36-0.70.360.360.530.360.410.36-0.17-0.460.38-0.460.22
0.99-0.99-0.72-1.0-0.93-1.0-1.0-1.0-0.990.991.00.99-0.360.12-1.0-1.0-0.79-1.0-1.0-1.00.980.99-0.970.99-0.99
0.28-0.01-0.78-0.120.2-0.12-0.15-0.12-0.010.120.120.19-0.70.12-0.12-0.130.1-0.12-0.16-0.12-0.010.2-0.310.20.02
-0.990.990.721.00.931.01.01.00.99-0.99-1.0-0.990.36-1.0-0.121.00.81.01.01.0-0.98-0.990.97-0.990.99
-0.990.990.721.00.931.01.01.00.99-0.99-1.0-1.00.36-1.0-0.131.00.81.01.01.0-0.98-0.990.97-0.990.99
-0.780.790.450.80.690.790.810.80.79-0.85-0.79-0.820.53-0.790.10.80.80.790.810.79-0.72-0.820.66-0.820.78
-0.990.990.721.00.931.01.01.00.99-0.99-1.0-0.990.36-1.0-0.121.01.00.791.01.0-0.98-0.990.97-0.990.99
-0.990.990.741.00.911.01.01.00.99-1.0-1.0-1.00.41-1.0-0.161.01.00.811.01.0-0.97-1.00.97-1.00.98
-0.990.990.721.00.931.01.01.00.99-0.99-1.0-0.990.36-1.0-0.121.01.00.791.01.0-0.98-0.990.97-0.990.99
0.94-0.99-0.61-0.98-0.98-0.98-0.97-0.98-0.990.960.980.96-0.170.98-0.01-0.98-0.98-0.72-0.98-0.97-0.980.95-0.950.95-1.0
1.0-0.97-0.77-0.99-0.89-0.99-1.0-0.99-0.971.00.991.0-0.460.990.2-0.99-0.99-0.82-0.99-1.0-0.990.95-0.971.0-0.97
-0.980.950.830.970.870.970.970.970.95-0.95-0.97-0.970.38-0.97-0.310.970.970.660.970.970.97-0.95-0.97-0.970.94
1.0-0.97-0.77-0.99-0.89-0.99-1.0-0.99-0.971.00.991.0-0.460.990.2-0.99-0.99-0.82-0.99-1.0-0.990.951.0-0.97-0.97
-0.951.00.610.990.980.990.980.991.0-0.98-0.99-0.970.22-0.990.020.990.990.780.990.980.99-1.0-0.970.94-0.97
Click cells to compare fundamentals

Nanobac Pharmaceuticals Account Relationship Matchups

Additional Tools for Nanobac Stock Analysis

When running Nanobac Pharmaceuticals' price analysis, check to measure Nanobac Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nanobac Pharmaceuticals is operating at the current time. Most of Nanobac Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Nanobac Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nanobac Pharmaceuticals' price. Additionally, you may evaluate how the addition of Nanobac Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.